• 25-Hydroxycholesterol Drives Macrophage Immunosuppression vi

  2026-04-27

  Xiao et al. (2024) reveal how tumor-associated macrophages (TAMs) accumulate 25-hydroxycholesterol (25HC), leading to lysosomal AMPKa activation and immunosuppressive reprogramming via the GPR155-mTORC1-STAT6 axis. Targeting CH25H disrupts this pathway, enhancing anti-tumor immune responses and improving efficacy of anti-PD-1 therapy.

• Birinapant (TL32711): Precision Modulation of Apoptosis Path

  2026-04-27

  Explore how Birinapant (TL32711) enables targeted apoptosis induction in cancer cells by modulating IAP-mediated signaling. This in-depth analysis reveals advanced assay strategies and unique insights from recent biomarker research.

• 5-(N,N-dimethyl)-Amiloride Hydrochloride: Applied Workflows

  2026-04-26

  5-(N,N-dimethyl)-Amiloride hydrochloride empowers researchers to unravel Na+/H+ exchanger signaling with high selectivity and reproducibility. This article delivers actionable protocols, troubleshooting strategies, and data-driven insights for advancing endothelial, cardiac, and metabolic research using APExBIO’s C3505.

• PYR-41: Redefining Ubiquitin E1 Inhibition for Translational

  2026-04-25

  This article delivers a rigorous yet forward-thinking perspective on leveraging PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1, as a strategic tool for translational researchers. We bridge mechanistic insights with actionable guidance, contextualize current evidence, and outline both opportunities and remaining challenges in protein degradation pathway research.

• AO/PI Double Staining Kit: Precision Apoptosis and Necrosis

  2026-04-24

  Explore how the AO/PI Double Staining Kit enables advanced apoptosis and necrosis detection using dual fluorescent dyes. This article uniquely focuses on drug-induced cell death, offering actionable insights for optimizing cell viability assays.

• Bradykinin B2 Receptor Modulation of Peristalsis in Guinea P

  2026-04-24

  This study elucidates the role of bradykinin B2 receptors in inhibiting the peristaltic reflex within the guinea pig isolated ileum using selective agonists and antagonists. The findings clarify receptor-specific modulation of intestinal motility, offering mechanistic insight relevant to gastrointestinal pharmacology and ACE inhibition research.

• Bufuralol Hydrochloride in Human-Relevant β-Adrenergic Resea

  2026-04-23

  Explore how Bufuralol hydrochloride, a non-selective β-adrenergic receptor antagonist, enables advanced and human-relevant cardiovascular pharmacology research. This article uniquely analyzes assay design, protocol parameters, and the impact of hiPSC-derived intestinal organoids, offering deeper insights than existing content.

• HyperScript First-Strand cDNA Synthesis Kit: Workflow Precis

  2026-04-23

  The HyperScript First-Strand cDNA Synthesis Kit empowers researchers to efficiently reverse transcribe complex and low-abundance RNA, supporting robust gene expression analysis. Its advanced enzyme engineering and versatile primer options streamline workflows for challenging templates, setting a new benchmark for PCR and qPCR applications.

• Risedronate Sodium in Translational Oncology: Beyond Bone Me

  2026-04-22

  Explore the advanced roles of Risedronate Sodium as a FPP synthase inhibitor in both bone metabolism and tumor cell line research. This article provides a unique, evidence-based perspective on its antiproliferative applications, experimental protocols, and translational potential.

• Mapping Allosteric Sites of GCGR for Small-Molecule Antagoni

  2026-04-22

  Wang et al. (2024) systematically identified and characterized multiple allosteric binding sites on the human glucagon receptor (GCGR) using a combination of crystal structures and molecular dynamics simulations. Their insights clarify the binding mode of MK 0893 and predict sites for other candidate antagonists, informing the design of next-generation therapies for type 2 diabetes.

• Morin Inhibits AMPD to Protect Podocyte Mitochondria in Fruc

  2026-04-21

  This study elucidates how Morin, a natural flavonoid (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one), mitigates fructose-induced mitochondrial dysfunction in podocytes by inhibiting adenosine 5′-monophosphate deaminase activity. The findings identify AMPD2 as a therapeutic target for glomerular injury and provide mechanistic insight into Morin’s potential in kidney disease models.

• PCMT1 Identified as Driver of Ovarian Cancer Metastasis via

  2026-04-21

  This study by Zhang et al. uses a genome-wide CRISPR/Cas9 screen to identify PCMT1 as a key factor in ovarian cancer metastasis, specifically through its role in promoting anoikis resistance and activating focal adhesion signaling. The findings suggest new therapeutic targets for metastatic ovarian cancer and provide a robust methodological framework for investigating ECM–tumor cell interactions.

• Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301): T

  2026-04-20

  Benzyl-activated Streptavidin Magnetic Beads (SKU: K1301) enable rapid, specific isolation of biotinylated molecules from complex biological samples, streamlining workflows for protein and nucleic acid purification, immunoprecipitation, and screening applications. They are not suitable for non-biotinylated target capture or workflows requiring beads with strong positive surface charge.

• Amitriptyline HCl: Technical Guide for Neuropharmacology Wor

  2026-04-20

  Amitriptyline HCl is a high-purity tricyclic small molecule for precise modulation of serotonin and norepinephrine receptors in neuropharmacology research. It is best suited for in vitro and ex vivo studies requiring defined neurotransmitter receptor inhibition and robust solubility, but is not validated for in vivo or clinical use without further evidence.

• Mitoxantrone HCl Targets ERα DBD-LBD Interface to Overcome R

  2026-04-19

  Wang et al. unveil a novel mechanism for estrogen receptor (ERα) inhibition by targeting the DNA-binding domain (DBD)–ligand-binding domain (LBD) interface using mitoxantrone HCl, a DNA topoisomerase II inhibitor. This approach induces proteasomal degradation of both wild-type and clinically relevant mutant ERα, offering a potential solution to therapeutic resistance in breast cancer.

16161 records 1/1078 page Next 12345 下5页 Last page